Kinetics and displacement of [11C]RO 15-1788, a benzodiazepine antagonist, studied in human brain in vivo by positron tomography.

The brain regional distribution and kinetics of RO 15-1788, a benzodiazepine (BZD) antagonist labeled with 11C was studied by time-of-flight positron tomography after intravenous injection in four normal human volunteers. In two control studies, there was a high uptake of [11C]RO 15-1788 in gray matter structures initially (brain/blood ratio approximately 3), and subsequent retention that was highest in cerebral cortex, a structure known to have a high density of BZD receptors in vitro. Variation in tissue kinetics of [11C]RO among different gray matter structures may, however, suggest regional differences in binding characteristics or environment of BZD receptors. In two displacement studies, unlabeled RO 15-1788 was injected ten minutes after the radioligand: there was an immediate and marked washout of [11C]brain radioactivity that reached 70% in the occipital cortex with a 0.05 mg/kg dose (indicating a high specific to non-specific binding ratio) but was less prominent with a 0.01 mg/kg dose. These data suggest that [11C]RO 15-1788 may be useful for in vivo mapping of human brain BZD receptors using positron tomography.

[1]  L. Pieri,et al.  Selective antagonists of benzodiazepines , 1981, Nature.

[2]  R. Naquet,et al.  RO 15 1788- 11C: A Specific Radioligand for an “in Vivo” Study of Central Benzodiazepine Receptors, by Positron Emission Tomography , 1984 .

[3]  R. Naquet,et al.  Central type benzodiazepine binding sites: A positron emission tomography study in the baboon's brain , 1984, Neuroscience Letters.

[4]  R. Naquet,et al.  Visualisation of 11C-flunitrazepam displacement in the brain of the live baboon , 1979, Nature.

[5]  C. Cepeda,et al.  The kinetics and displacement of [11C]flunitrazepam in the brain of the living baboon. , 1981, European journal of pharmacology.

[6]  G. Scollo-Lavizzari First clinical investigation of the benzodiazepine antagonist Ro 15-1788 in comatose patients. , 1983, European neurology.

[7]  Dopaminergic receptor sites in human brain , 1985, Neurology.

[8]  F. Soussaline,et al.  Physical characterization of a time-of-flight positron emission tomography system for whole-body quantitative studies , 1984 .

[9]  R. Naquet,et al.  76Br-bromospiroperidol: a new tool for quantitative in-vivo imaging of neuroleptic receptors. , 1984, Life sciences.

[10]  J. Mazziotta,et al.  Tomographic mapping of human cerebral metabolism , 1981, Neurology.

[11]  B. Guibert,et al.  11C-Ro 15-1788 et 11C-flunitrazepam, deux coordinats pour l'étude par tomographie par positons des sites de liaison des benzodiazépines. , 1983 .

[12]  I. Martin,et al.  Kinetics of [3H]Ro 15–1788 Binding to Membrane‐Bound Rat Brain Benzodiazepine Receptors , 1984, Journal of neurochemistry.

[13]  J. Baron,et al.  Brain regional pharmacokinetics of 11‐labeled diphenylhydantoin , 1983, Neurology.

[14]  D Comar,et al.  Synthesis of ethyl 8-fluoro-5,6-dihydro-5-[11C]methyl-6-oxo-4H-imidazo [1,5-a] [1,4]benzodiazepine-3-carboxylate (RO 15.1788-11C): a specific radioligand for the in vivo study of central benzodiazepine receptors by positron emission tomography. , 1984, The International journal of applied radiation and isotopes.

[15]  A. Syrota,et al.  Kinetics of in vivo binding of antagonist to muscarinic cholinergic receptor in the human heart studied by positron emission tomography. , 1984, Life sciences.

[16]  Jonathan M. Links,et al.  Imaging dopamine receptors in the human brain by positron tomography , 1983 .

[17]  J C Mazziotta,et al.  Quantitation in Positron Emission Computed Tomography: 5. Physical–Anatomical Effects , 1981, Journal of computer assisted tomography.

[18]  K. Mullis,et al.  Opiate antagonist receptor binding in vivo: evidence for a new receptor binding model , 1980, Brain Research.